RE:RE:RE:RE:BiOasis Vs Annexon!Why the comparison with Annexon?,,,and our Zack target is 92 cents CAD.
Good question,,, I have been looking thru some of the data from ANNX and they are certainly ahead of us based on what BTI has compiled around its xB3.
However with the Cresense deal I cant decipher ruffly where we are now with these assets.
We are told we bought ,,,"Phase 2 ready assets aligned with our focus in rare disease and orphan drug indications. EGF1-48 comes with a full IND package and clinical experience indicating that it is safe and well tolerated in humans."
But, does this equate to a similar level of advancement as Annexon??,,,,it just a tad confusing. Based on share price at present it seesm we dont have the same size market,,,nor the same ability to effect,,,,nor the level of advancement. You pick.